6.
Messerli F, Bangalore S
. Lowering the Thresholds of Diseases: Is Anyone Still Healthy?. J Am Coll Cardiol. 2018; 71(2):119-121.
DOI: 10.1016/j.jacc.2017.11.029.
View
7.
Beddhu S, Greene T, Boucher R, Cushman W, Wei G, Stoddard G
. Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials. Lancet Diabetes Endocrinol. 2018; 6(7):555-563.
PMC: 6071316.
DOI: 10.1016/S2213-8587(18)30099-8.
View
8.
. Indian guidelines on hypertension (I.G.H.) - III. 2013. J Assoc Physicians India. 2014; 61(2 Suppl):6-36.
View
9.
Deedwania P
. Blood pressure control in diabetes mellitus: is lower always better, and how low should it go?. Circulation. 2011; 123(24):2776-8.
DOI: 10.1161/CIRCULATIONAHA.111.033704.
View
10.
de Boer I, Bakris G, Cannon C
. Individualizing Blood Pressure Targets for People With Diabetes and Hypertension: Comparing the ADA and the ACC/AHA Recommendations. JAMA. 2018; 319(13):1319-1320.
DOI: 10.1001/jama.2018.0642.
View
11.
Bohn B, Schofl C, Zimmer V, Hummel M, Heise N, Siegel E
. Achievement of treatment goals for secondary prevention of myocardial infarction or stroke in 29,325 patients with type 2 diabetes: a German/Austrian DPV-multicenter analysis. Cardiovasc Diabetol. 2016; 15:72.
PMC: 4855873.
DOI: 10.1186/s12933-016-0391-8.
View
12.
Garcia-Touza M, Sowers J
. Evidence-based hypertension treatment in patients with diabetes. J Clin Hypertens (Greenwich). 2012; 14(2):97-102.
PMC: 3270694.
DOI: 10.1111/j.1751-7176.2011.00570.x.
View
13.
Bakris G, Sorrentino M
. Redefining Hypertension - Assessing the New Blood-Pressure Guidelines. N Engl J Med. 2018; 378(6):497-499.
DOI: 10.1056/NEJMp1716193.
View
14.
Mancia G, Grassi G
. Blood pressure targets in type 2 diabetes. Evidence against or in favour of an aggressive approach. Diabetologia. 2018; 61(3):517-525.
DOI: 10.1007/s00125-017-4537-3.
View
15.
Visseren F, Mach F, Smulders Y, Carballo D, Koskinas K, Back M
. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34):3227-3337.
DOI: 10.1093/eurheartj/ehab484.
View
16.
Buckley L, Dixon D, Wohlford 4th G, Wijesinghe D, Baker W, Van Tassell B
. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP. Diabetes Care. 2017; 40(12):1733-1738.
DOI: 10.2337/dc17-1366.
View
17.
Cushman W, Evans G, Byington R, Goff Jr D, Grimm Jr R, Cutler J
. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17):1575-85.
PMC: 4123215.
DOI: 10.1056/NEJMoa1001286.
View
18.
Cooper-DeHoff R, Gong Y, Handberg E, Bavry A, Denardo S, Bakris G
. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010; 304(1):61-8.
PMC: 3008411.
DOI: 10.1001/jama.2010.884.
View
19.
Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A
. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018; 380(4):347-357.
DOI: 10.1056/NEJMoa1812389.
View
20.
James P, Oparil S, Carter B, Cushman W, Dennison-Himmelfarb C, Handler J
. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2013; 311(5):507-20.
DOI: 10.1001/jama.2013.284427.
View